Baxter International Inc (BAX)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $13.35B
Last updated: Nov 17, 2026 at 11:05 AM ET
Baxter International Inc (BAX) Stock Forecast
Analysts expect Baxter International (BAX) to earn $2.11 per share in the fiscal year ending Dec 31, 2026, on revenue of $11.72B. Of 15 analysts, 2 rate the stock Buy or Strong Buy, 12 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 13 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.93, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 13% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 6.7% |
| Buy | 1 | 6.7% |
| Hold | 12 | 80.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 6.7% |
- Consensus
- Hold
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 2.8% and revenue estimates rise 2.0%.
- Fiscal year ending Dec 31, 2026
- $2.11
- EPS consensus, revenue $11.72B
- Fiscal year ending Dec 31, 2027
- $2.05
- EPS consensus, revenue $11.96B
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.11 | $2.07 to $2.15 | 15 | $11.72B | $11.69B to $11.76B | 13 |
| Dec 31, 2027 | $2.05 | $1.95 to $2.12 | 15 | $11.96B | $11.81B to $12.14B | 13 |
Quarterly Estimates
The EPS consensus falls from $0.60 for the quarter ending Dec 31, 2026 to $0.41 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.60 | $0.56 to $0.64 | 15 | $3.12B | $3.00B to $3.28B | 14 |
| Mar 31, 2027 | $0.41 | $0.35 to $0.51 | 8 | $2.76B | $2.75B to $2.79B | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 21 upward and 10 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 13 | 0 |
| Fiscal year ending Dec 31, 2027 | 6 | 7 |
| Quarter ending Mar 31, 2027 | 2 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.9% from $2.05.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.11 | $2.10 | $2.05 | $2.05 | $2.05 | +2.8% |
| Fiscal year ending Dec 31, 2027 | $2.05 | $2.04 | $2.04 | $2.04 | $2.04 | +0.4% |
| Quarter ending Mar 31, 2027 | $0.41 | $0.41 | $0.44 | $0.45 | $0.45 | -8.6% |
Frequently Asked Questions About BAX
What is the BAX stock forecast?
Consensus analyst estimates put Baxter International's EPS at $2.11 for the fiscal year ending Dec 31, 2026, on revenue of $11.72B. The consensus rating from 15 analysts is Hold.
How do analysts rate BAX stock?
Of 15 analysts covering Baxter International, 1 rates it Strong Buy, 1 Buy, 12 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from BAX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.11, with estimates from $2.07 to $2.15 from 15 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.05, with estimates from $1.95 to $2.12 from 15 analysts.
What revenue do analysts expect from Baxter International next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $11.72B, with estimates from $11.69B to $11.76B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $11.96B, with estimates from $11.81B to $12.14B.
How many analysts cover BAX?
15 analysts rate Baxter International stock, and 15 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BAX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors